Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Amortizatization of Intangibles: 2015-2024

Historic Amortizatization of Intangibles for Corvus Pharmaceuticals (CRVS) over the last 10 years, with Dec 2024 value amounting to $1.1 million.

  • Corvus Pharmaceuticals' Amortizatization of Intangibles fell 12.40% to $459,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 29.24%. This contributed to the annual value of $1.1 million for FY2024, which is 27.63% up from last year.
  • According to the latest figures from FY2024, Corvus Pharmaceuticals' Amortizatization of Intangibles is $1.1 million, which was up 27.63% from $894,000 recorded in FY2023.
  • Corvus Pharmaceuticals' Amortizatization of Intangibles' 5-year high stood at $1.1 million during FY2024, with a 5-year trough of $154,000 in FY2020.
  • Over the past 3 years, Corvus Pharmaceuticals' median Amortizatization of Intangibles value was $894,000 (recorded in 2023), while the average stood at $735,000.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first decreased by 28.87% in 2022, then surged by 425.88% in 2023.
  • Over the past 5 years, Corvus Pharmaceuticals' Amortizatization of Intangibles (Yearly) stood at $154,000 in 2020, then spiked by 55.19% to $239,000 in 2021, then dropped by 28.87% to $170,000 in 2022, then soared by 425.88% to $894,000 in 2023, then increased by 27.63% to $1.1 million in 2024.